Pathios Therapeutics website screenshot

Pathios Therapeutics

Pathios Therapeutics is a clinical-stage oncology and immunology drug discovery and development company based in Oxfordshire, United Kingdom, founded in 2017. The company develops small-molecule inhibitors of the pH-sensing G protein-coupled receptor GPR65 to counteract the immunosuppressive tumor microenvironment; its lead asset PTT-4256 is a first-in-class GPR65 inhibitor now in a Phase 1/2 clinical trial. Backed by Canaan, Brandon Capital, and a strategic investment from Bristol Myers Squibb, Pathios is a research-stage biotech with no public API, developer platform, or technical integration surface. This profile was surfaced as a portfolio company of canaan-partners and processed by the enrichment pipeline, which confirmed there is no API surface to catalog.

Pathios Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Immunology.

Pathios Therapeutics’ developer surface includes product news and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub
2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyBiotechnologyPharmaceuticalsOncologyImmunologyDrug DiscoveryClinical StageLife Sciences

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 2.2/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 0.0 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/pathios-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Operate 1

Status, limits, changes, and where to get help

Contact
Contact

Company 4

The organization behind the API

Website
Website
 About
About
 News
News
 LinkedIn
LinkedIn

Source (apis.yml)

apis.yml Raw ↑ 
aid: pathios-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/pathios-therapeutics.png
name: Pathios Therapeutics
description: Pathios Therapeutics is a clinical-stage oncology and immunology drug discovery and development company based
  in Oxfordshire, United Kingdom, founded in 2017. The company develops small-molecule inhibitors of the pH-sensing G protein-coupled
  receptor GPR65 to counteract the immunosuppressive tumor microenvironment; its lead asset PTT-4256 is a first-in-class GPR65
  inhibitor now in a Phase 1/2 clinical trial. Backed by Canaan, Brandon Capital, and a strategic investment from Bristol
  Myers Squibb, Pathios is a research-stage biotech with no public API, developer platform, or technical integration surface.
  This profile was surfaced as a portfolio company of canaan-partners and processed by the enrichment pipeline, which confirmed
  there is no API surface to catalog.
url: https://raw.githubusercontent.com/api-evangelist/pathios-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Immunology
- Drug Discovery
- Clinical Stage
- Life Sciences
apis: []
common:
- type: Website
  url: https://pathiostherapeutics.com/
- type: About
  url: https://pathiostherapeutics.com/about-us/
- type: News
  url: https://pathiostherapeutics.com/news/
- type: Contact
  url: https://pathiostherapeutics.com/contact-us/
- type: LinkedIn
  url: https://uk.linkedin.com/company/pathios-therapeutics-limited
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1